New Study in Neurology Highlights the Potential of Quantitative MRI Biomarkers for Assessing Muscle Changes in SBMA
AMRA Medical has announced the publication of new research in Neurology demonstrating the potential of quantitative whole-body magnetic resonance imaging (MRI) to measure disease-related changes in patients with spinal and bulbar muscular atrophy (SBMA). The study provides further evidence that advanced MRI-based assessments of muscle composition could serve as objective biomarkers for tracking progression in rare neuromuscular diseases.
The research, titled “Muscle MRI as an imaging biomarker of muscle damage in patients with spinal and bulbar muscular atrophy,” was also selected for the cover of the latest issue of Neurology, highlighting the significance of the findings to the broader field of clinical neurology and neuromuscular disease research.
SBMA, also known as Kennedy disease, is a rare, inherited neuromuscular disorder characterized by progressive weakness and wasting of muscles. The disease primarily affects motor neurons and can lead to deterioration in muscle function over time. Because SBMA generally progresses gradually and can vary considerably among patients, accurately measuring disease progression remains an important challenge for researchers developing potential treatments.
Traditional clinical assessments can provide valuable information about a patient’s physical capabilities, but functional measures may not always capture subtle biological changes occurring within muscles. This creates a need for sensitive, reproducible tools that can complement established clinical evaluations and potentially provide earlier indications of disease-related changes.
The newly published study investigated whether quantitative whole-body MRI could address some of these challenges by providing detailed measurements of changes in muscle composition over time.
Study Evaluates MRI-Based Measures of Muscle Composition
Researchers used AMRA® Researcher to analyze quantitative whole-body MRI scans from 25 participants with SBMA. The objective was to determine whether MRI-derived measurements could detect longitudinal changes in muscle composition and whether these imaging measures were associated with established assessments of disease severity and physical function.
Unlike conventional MRI assessments that are often interpreted primarily through visual examination, quantitative MRI can generate measurable information about tissue composition. In the context of neuromuscular disease, this approach can be used to evaluate changes such as the accumulation of fat within muscles and reductions in healthy muscle tissue.
The researchers focused on fat-referenced MRI measurements as a means of evaluating muscle damage and composition. Participants underwent imaging assessments that allowed the research team to examine changes over a 12-month period.
By collecting quantitative measurements across the body, whole-body MRI provides researchers with a broader view of muscle involvement than assessments focused on individual muscles or anatomical regions. This may be particularly valuable for disorders such as SBMA, in which muscle weakness and degeneration can develop across multiple areas of the body.
MRI Detected Significant Changes Over 12 Months
One of the key findings from the study was that MRI-derived measures detected significant changes in muscle composition during the 12-month observation period.
The ability to identify measurable changes over a relatively defined period is important in clinical research involving slowly progressive neuromuscular disorders. In diseases where functional deterioration may occur gradually, conventional clinical endpoints can sometimes require extended observation periods before meaningful differences become apparent.
The findings suggest that quantitative MRI may be sufficiently responsive to detect changes associated with SBMA progression. This responsiveness could make imaging biomarkers useful as complementary measures in future natural-history studies and clinical trials.
Importantly, the study did not establish quantitative MRI as a replacement for clinical assessments. Instead, the results indicate that MRI measurements may provide an additional source of objective information about disease-related changes in muscle tissue.
Correlation With Established Clinical Outcomes
The researchers also examined the relationship between baseline MRI measurements and established clinical measures of SBMA severity and function.
Baseline MRI measurements were correlated with scores from the Spinal and Bulbar Muscular Atrophy Functional Rating Scale (SBMAFRS) and performance on the 2-Minute Walk Test. These associations suggest that quantitative muscle composition measurements may reflect aspects of functional disease burden in people living with SBMA.
The SBMAFRS is designed to assess functional impairment associated with the disease, while the 2-Minute Walk Test provides a measure of walking capacity and physical performance. By identifying relationships between imaging biomarkers and these established clinical assessments, the study provides preliminary evidence that quantitative MRI may have relevance to clinically meaningful aspects of SBMA.
However, the researchers emphasized that additional investigation is needed to better understand these relationships. Larger studies and longer follow-up periods will be important to determine how MRI-derived measures correspond with functional changes and whether they can reliably predict clinical progression.
Potential Role in Neuromuscular Disease Research
The findings contribute to a growing body of research examining quantitative MRI as a biomarker in neuromuscular disorders. Biomarkers that can objectively measure biological changes may be particularly valuable in rare diseases, where clinical studies can face challenges related to small patient populations, disease variability and slow rates of progression.
SBMA is one example of a condition in which measuring progression can be difficult. Patients may experience different patterns and rates of muscle deterioration, while traditional functional tests can be influenced by factors unrelated to the underlying changes in muscle tissue.
Quantitative MRI offers a complementary approach by directly measuring aspects of muscle composition. Detecting changes in muscle fat and other tissue characteristics could help researchers obtain a more detailed understanding of how disease affects skeletal muscle over time.
Such measurements could potentially support several areas of drug development. Researchers may use imaging biomarkers to characterize disease progression in natural-history studies, assess biological responses to investigational treatments, or help determine appropriate endpoints for clinical trials.
For sponsors developing therapies for rare neuromuscular conditions, reproducible quantitative measures may also help address the limitations associated with relying exclusively on functional outcomes.
Expanding Applications Across Neuromuscular Diseases
The publication in Neurology represents another step in the development of evidence supporting quantitative whole-body MRI in neuromuscular research. According to AMRA Medical, the company has been working across a range of neuromuscular diseases, including both rapidly and slowly progressing disorders and inflammatory myopathies.
This research activity has included conditions such as facioscapulohumeral muscular dystrophy (FSHD), Duchenne muscular dystrophy (DMD) and sporadic inclusion body myositis (sIBM). Investigating MRI biomarkers across diseases with different mechanisms and progression patterns may help researchers understand where quantitative imaging can provide the greatest value.
The broader objective is to establish imaging measures that are objective, sensitive and reproducible enough to complement traditional clinical endpoints.
As the development pipeline for rare neuromuscular diseases continues to expand, these tools could become increasingly relevant. Pharmaceutical and biotechnology companies are pursuing new therapeutic approaches for disorders that historically have had limited treatment options, increasing the need for reliable methods to measure treatment effects.
Importance for Future Clinical Trials
A major potential application of quantitative MRI is clinical trial endpoint development. Clinical trials in slowly progressing diseases may require substantial time and patient participation to demonstrate meaningful changes in functional outcomes. An imaging biomarker capable of detecting changes in muscle composition could potentially provide researchers with additional information during this process.
However, imaging biomarkers must undergo rigorous validation before they can be considered definitive clinical trial endpoints. Researchers need to establish their reliability, reproducibility, sensitivity to disease progression and relationship to outcomes that matter to patients.
The current SBMA study provides encouraging evidence but represents an important step within that broader validation process. The relatively small cohort of 25 participants means that further studies involving larger and more diverse populations will be necessary.
Longer-term research could also help determine whether changes in MRI-derived muscle composition are associated with future functional decline and whether treatment-related changes on MRI correspond with meaningful clinical benefits.
Building Evidence for Quantitative MRI in SBMA
The publication of the study in Neurology adds to the scientific evidence supporting quantitative whole-body MRI as a potential tool for neuromuscular disease research. By demonstrating that MRI-based measurements can detect significant changes in muscle composition over 12 months and show associations with established clinical assessments, the research provides a foundation for further investigation in SBMA.
The selection of the study for the journal’s cover further emphasizes the visibility of this work within the neuromuscular research community.
As researchers continue to explore new therapies for SBMA and other rare neuromuscular diseases, objective biomarkers could play an increasingly important role in understanding disease biology and evaluating therapeutic interventions. Quantitative MRI may ultimately complement functional assessments by providing measurable information about changes taking place within muscle tissue.
The authors’ findings therefore support continued research into MRI-based biomarkers while underscoring the need for additional validation. Future studies may help clarify how these imaging measures relate to disease progression, functional impairment and treatment response.
The full manuscript is available in the latest issue of Neurology and is identified by DOI 10.1212/WNL.0000000000218309.
About AMRA Medical
AMRA Medical is a global leader in health informatics, pioneering the field of fat and muscle analysis with proprietary, MRI-based technologies. Our gold-standard platform delivers highly precise and standardized biomarkers, providing an advanced understanding of metabolic and musculoskeletal health that surpasses conventional body composition metrics. These insights play a critical role in optimizing clinical trial design, improving endpoint selection, and supporting data-driven decision-making in both research and clinical practice.
Built on rigorous science and driven by continuous innovation, AMRA’s solutions are designed to meet the complex demands of modern healthcare and pharmaceutical development. Through standardized, cloud-based workflows and strategic collaboration, we enable partners to access actionable data with clarity and confidence–accelerating progress from early-stage discovery to impactful clinical outcomes.